William J. Lowery

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu

Amanda N. Fader, Dana M. Roque, Eric R. Siegel et al. · Journal of Clinical Oncology · 2018 · 525 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis

Amanda N. Fader, Dana M. Roque, Eric R. Siegel et al. · Clinical Cancer Research · 2020 · 308 citations · Full text

Medicine, Oncology, Pharmacology +17

Loss of ARID1A-Associated Protein Expression is a Frequent Event in Clear Cell and Endometrioid Ovarian Cancers

William J. Lowery, Joellen M. Schildkraut, Rex C. Bentley et al. · International Journal of Gynecological Cancer · 2011 · 99 citations · Full text

Medicine, Gynecology, Oncology +17

Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer

William J. Lowery, Ashlei W. Lowery, Jason C. Barnett et al. · Gynecologic Oncology · 2013 · 68 citations

Medicine, Oncology, Pharmacoeconomics +13

Oral contraceptive use for the primary prevention of ovarian cancer.

Laura J. Havrilesky, Jennifer M. Gierisch, Patricia G. Moorman et al. · PubMed · 2013 · 52 citations

Medicine, Gynecology, Oncology +17